Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inspire IVF PCL's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 0.25.
Inspire IVF PCL's Days Inventory for the
three
months ended in Mar. 2026 was 21.76.
Inspire IVF PCL's Days Payable for the
three
months ended in Mar. 2026 was 17.28.
Therefore, Inspire IVF PCL's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 4.73.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Inspire IVF PCL Cash Conversion Cycle Related Terms
Inspire IVF PCL Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Inspire IVF PCL's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:IVF vs HCA, THC, DVA: Cash Conversion Cycle Comparison
For the Medical Care Facilities subindustry, Inspire IVF PCL's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inspire IVF PCL Cash Conversion Cycle vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Inspire IVF PCL's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Inspire IVF PCL's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Inspire IVF PCL's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inspire IVF PCL (BKK:IVF) has a Cash Conversion Cycle of 4.73 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Inspire IVF PCL and its competitors.
Is Inspire IVF PCL's Cash Conversion Cycle too high?
Inspire IVF PCL's current Cash Conversion Cycle is 4.73. The Healthcare Providers & Services industry median Cash Conversion Cycle is 18.01. Inspire IVF PCL's value of 4.73 is 73.7% below this industry median. Overall, Inspire IVF PCL has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Inspire IVF PCL's Cash Conversion Cycle compare to HCA and THC?
Inspire IVF PCL's Cash Conversion Cycle of 4.73 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash Conversion Cycle is 18.01. Inspire IVF PCL's value of 4.73 is 73.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Healthcare Providers & Services company?
The median Cash Conversion Cycle among Healthcare Providers & Services companies is 18.01, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inspire IVF PCL's current Cash Conversion Cycle of 4.73 is 73.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Inspire IVF PCL and its competitors. For the Healthcare Providers & Services industry, the median Cash Conversion Cycle is 18.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inspire IVF PCL's current Cash Conversion Cycle is 4.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inspire IVF PCL stock overvalued right now?
Inspire IVF PCL (BKK:IVF) has a current Cash Conversion Cycle of 4.73. The current Cash Conversion Cycle is 4.73 and 73.7% below the Healthcare Providers & Services industry median of 18.01. Inspire IVF PCL's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Inspire IVF PCL (BKK:IVF), the current Cash Conversion Cycle is 4.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inspire IVF PCL operates a comprehensive fertility treatment center, offering services ranging from consultations to selecting the appropriate treatment for each couple. It is principally engaged in infertility treatment and counseling services treatment with anti-aging medicine and health restoration, hemodialysis, blood filtration, and plasma filtration. The company operates in a single geographic area, Thailand.
18GF Score
Get the complete analysis for BKK:IVF
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:IVF has been successfully added to your 
